|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM159027950 |
| 003 |
DE-627 |
| 005 |
20250206211225.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0530.xml
|
| 035 |
|
|
|a (DE-627)NLM159027950
|
| 035 |
|
|
|a (NLM)16297664
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Broides, Arnon
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Genotype/phenotype correlations in X-linked agammaglobulinemia
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.03.2006
|
| 500 |
|
|
|a Date Revised 01.12.2018
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a No clear genotype/phenotype correlations have been established in patients with X-linked agammaglobulinemia (XLA). To determine if the specific mutation in Btk might be one of the factors that influences the severity of disease or if polymorphic variants in Tec, a cytoplasmic tyrosine kinase that might substitute for Btk, could contribute to the clinical phenotype, we examined the age at diagnosis, the percentage of peripheral blood B cells and the plasma IgM in a large group of patients with XLA. The results demonstrated that polymorphic variants in Tec were not correlated with phenotypic markers; however, the specific mutation in Btk did influence disease severity. Mutations that conceivably allow the production of some Btk, amino acid substitutions or splice defects that occur at conserved but not invariant sites in the splice consensus sequence were associated with older age at diagnosis, a higher percentage of B cells in the peripheral circulation and higher concentrations of plasma IgM
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 650 |
|
7 |
|a Tec protein-tyrosine kinase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.1.-
|2 NLM
|
| 650 |
|
7 |
|a Protein-Tyrosine Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 650 |
|
7 |
|a Agammaglobulinaemia Tyrosine Kinase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a BTK protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 700 |
1 |
|
|a Yang, Wenjian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Conley, Mary Ellen
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 118(2006), 2-3 vom: 18. Feb., Seite 195-200
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:118
|g year:2006
|g number:2-3
|g day:18
|g month:02
|g pages:195-200
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 118
|j 2006
|e 2-3
|b 18
|c 02
|h 195-200
|